Silent. Precise. Potent.
Shinobi Therapeutics is a Japan-US biotechnology company developing immune-evasive iPSC-derived cell therapies for cancer and autoimmune diseases. Its proprietary Katana platform engineers hypoimmune iPS cells that evade both innate and antibody-mediated immune rejection, enabling off-the-shelf allogeneic therapies without the need for immunosuppression. Rooted in research from Kyoto University and UCSF, Shinobi launched in 2023 with a $51M Series A.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2024
Aug 2024
Dec 2023
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
